Company Profile
ImmunityBio Stock Price, News & Analysis
- Ticker:
- IBRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.99 USD (-1.55%)
Close
Last updated: July 27, 2026
7.57B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, IBRX closed down 1.55% at $6.99. No new same-company headline was identified in the current news window.
Company overview
Business overview
ImmunityBio is an immunotherapy company focused on cancer and immune-system activation, with a portfolio spanning cell therapy and biologics. Its story is built around creating broad anti-cancer immune responses.
Geographic Base and Sector Classification
ImmunityBio is headquartered in the United States and listed on NASDAQ. It sits in oncology biotechnology with a platform-immunotherapy identity.
Business Model Characteristics
The company depends on commercialization, clinical data, and the ability to scale a broad immunotherapy platform. Investors watch launch execution, efficacy, and manufacturing readiness.
Position Within the Biotechnology Landscape
ImmunityBio occupies a premium but complex oncology-immunotherapy niche within biotech. It has more commercial depth than many small-cap names, yet remains catalyst-sensitive because platform execution is still central.
Future catalysts
ImmunityBio’s catalysts are Anktiva launch execution, the bladder-cancer franchise, and any additional label or commercial step. The stock is still driven by whether the launch can keep scaling.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ImmunityBio (IBRX)?
ImmunityBio (IBRX) most recently closed at 6.99 USD, a -1.55% move versus the previous session.
What is the market cap of ImmunityBio (IBRX)?
ImmunityBio currently has a market capitalization of 7.57B USD on BioPharmSignal.
What does ImmunityBio do?
ImmunityBio is an immunotherapy company focused on cancer and immune-system activation, with a portfolio spanning cell therapy and biologics. Its story is built around creating broad anti-cancer immune responses.
On which exchange is IBRX stock listed?
ImmunityBio (IBRX) is associated with NASDAQ, United States, Biopharma.
What is ImmunityBio?
ImmunityBio’s catalysts are Anktiva launch execution, the bladder-cancer franchise, and any additional label or commercial step.
Which conditions is ImmunityBio targeting with ImmunityBio?
ImmunityBio is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does ImmunityBio describe recent progress with ImmunityBio?
ImmunityBio’s catalysts are Anktiva launch execution, the bladder-cancer franchise, and any additional label or commercial step.
What is Anktiva?
ImmunityBio’s catalysts are Anktiva launch execution, the bladder-cancer franchise, and any additional label or commercial step.